Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Basilea appoints Ronald Scott as CEO to succeed Anthony Man and expands management team

BASEL, SWITZERLAND -- (Marketwire) -- 12/10/12 -- Basilea Pharmaceutica AG / Basilea appoints Ronald Scott as CEO to succeed Anthony Man and expands management team.

Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has promoted Ronald Scott, previously Chief Operating Officer, to Chief Executive Officer effective January 1, 2013 to succeed Anthony Man, MD, who has decided for personal reasons to leave the company as of December 31, 2012.

"We are very pleased that Ron Scott will assume the role of CEO of Basilea following the decision of Anthony Man to resign. Ron Scott is an esteemed business leader in the pharmaceutical industry with a track record of delivering results and maintaining organization focus on business priorities. With several product candidates including highly competitive late-stage drugs in our pipeline and a strong cash position, Basilea has unique prospects to further create substantial shareholder value," commented Werner Henrich, chairman of Basilea. "Anthony Man is one of the most experienced and respected drug development executives in industry with an exceptional track record in bringing drugs through to the market. We sincerely thank him for his leadership, integrity and resilience in guiding Basilea through very rewarding and challenging times and wish him all the best for his future endeavors."

For the last year Ron Scott served as COO responsible for all of Basilea's operations including technical operations, commercial activities and finance. Prior to his position as COO he served as Basilea's CFO. Ron Scott led the company's equity financings and significant business transactions. Previously he held senior management positions in the pharmaceutical industry with over twenty years of experience and in the financial sector.

Basilea's Management Committee has been enlarged to include Ms. Heidi McDaid, Head of Global Human Resources effective January 1, 2013. The Management Team's other members remain Prof. Dr. Achim Kaufhold, Chief Medical Officer since 2010; Dr. Ingrid Heinze-Krauss, Chief Technical Officer since 2006; Dr. Laurenz Kellenberger, Chief Scientific Officer since 2009; and Joachim Blatter, Chief Financial Officer since 2012.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. ("Basilea") the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from www.basilea.com.

Press release (PDF):

http://hugin.info/134390/R/1663509/539483.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

[HUG#1663509]

For further information, please contact:

Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact |

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Earlier, I wrote a bit about traffic and the IoT. It's a big topic. The traffic problems of the developed and developing worlds seem so large, complex, and intractable to significant change in any reasonable timeframe. Consider Mexico City. There are more than 20 million people in ...
Is it just me, or has there been an explosion of buzz words lately? Don’t get me wrong, the IT industry innovates at a crazy pace normally, but it seems that things have been evolving faster than ever and that a fundamental change in the way things are done is underway. We can attribut...
My favorite writer, Gil Press, sums it up with, “It’s Official: The Internet Of Things Takes Over Big Data As The Most Hyped Technology” where he talks about how Gartner released its latest Hype Cycle for Emerging Technologies, and how big data has moved down the “trough of disillusion...
More and more Web sites and applications are being moved from Apache to nginx. While Apache is still the number one HTTP server with more than 60% on active Web sites, nginx has now taken over the 2nd place in the ranking and relegated Microsoft’s IIS to 3rd place. Among the top 10.000...
Getting one's arms around the Internet of Things is a daunting task. In addition to big IoT commitments from all of the big players in computing and telco, there are a number of smaller companies and startups working on devices and services to enable the future of enterprise IT and per...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE